Whole exome sequencing in unclassified autoinflammatory diseases: more monogenic diseases in the pipeline?

Abstract

WES strategy is cost-effective and provides substantial results for a selected group of undefined AID patients. Our results will contribute to the spectrum of unclassified AIDs.